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Abstract: Paroxysmal nocturnal hemoglobinuria is a rare disorder of hemopoietic stem cells. 
Affected individuals have a triad of clinical associations – intravascular hemolysis, an increased 
risk of thromboembolism, and bone marrow failure. Most of the symptoms experienced in this 
disease occur due to the absence of complement regulatory proteins on the surface of the red 
blood cells. Complement activation is thus not checked and causes destruction of these cells. 
Eculizumab is a monoclonal antibody treatment which specifically binds to the complement 
protein C5, preventing its cleavage, and so halts the complement cascade and prevents the 
formation of the terminal complement proteins. Eculizumab prevents intravascular hemolysis, 
stabilizes hemoglobin levels, reduces or stops the need for blood transfusions, and improves 
fatigue and patient quality of life as well as reducing pulmonary hypertension, decreasing the 
risk of thrombosis and protecting against worsening renal function. It is not a curative therapy 
but has a great benefit on those with this rare debilitating condition.
Keywords: eculizumab, paroxysmal nocturnal hemoglobinuria, hemolysis
Introduction
Eculizumab is a humanized monoclonal antibody which binds to the complement 
protein 5 (C5), thereby inhibiting the formation of the terminal components of the 
complement cascade.1 It was licensed by the Food and Drug Administration in March 
2007 and by the European Medicines Agency in June 2007 for the treatment of 
paroxysmal nocturnal hemoglobinuria (PNH). It has been shown to be a well tolerated 
and highly effective treatment for patients with PNH.2–4 PNH is a rare hematological 
disorder where hematological stem cells (HSCs) acquire an abnormality that is then 
passed on to their progeny. The red blood cells derived from these abnormal HSCs 
are extremely sensitive to complement mediated lysis which leads to many of the 
symptoms of the disease.5 Prior to eculizumab, treatment was mainly supportive in 
nature with a median survival of 10 to 15 years for patients treated between 1940 and 
1970.6 More recently, data from France reported a median survival of 22 years.7 This 
increase in survival may reflect improved supportive care as well as better treatment 
of more specific complications, such as thromboses.
The genetic defect
The disease is characterized by hemopoietic clones which harbor somatic muta-
tions of the phosphatidylinositol glycan synthetic pathway due to inactivation of the 
complementation class A gene (PIG-A).8 The PIG-A gene is one of a number of genes 
needed for the synthesis of the glycophosphatidylinositol (GPI) anchor within the Therapeutics and Clinical Risk Management 2009:5 912
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endoplasmic reticulum (ER).9 GPI biosynthesis occurs via 
a stepwise addition of sugar nucleotides and phospholipids 
within the ER before the completed protein is transferred 
to the cell surface10 (Figure 1). The GPI moiety serves as 
a membrane anchor for a variety of cell surface proteins. 
Mutations of the PIG-A gene disrupt the first step of GPI 
biosynthesis leading to an absence of the GPI anchor and, in 
turn, a marked deficiency of all GPI linked proteins.11
PIG-A is located on the X chromosome and is mono-
allelically expressed. All the other genes involved in GPI 
biosynthesis are autosomal. A single mutation in the PIG-A 
gene is therefore sufficient to disrupt GPI assembly leading 
to complete loss of function. For the remainder of genes in 
this pathway, both alleles would need to be mutated in the 
same cell to affect GPI production. This explains why all 
cases of acquired PNH which have been examined, harbor 
PIG-A mutations.12,13
The complement cascade 
and hemolysis in PNH
The complement cascade is an integral part of the innate 
immune system. It involves sequential reactions that 
ultimately cause cell lysis either by opsonization and sub-
sequent cell phagocytosis, or by the formation of a phos-
pholipase, called the membrane attack complex (MAC) 
that punches holes in the cell membrane (Figure 2). CD55 
(decay accelerating factor, DAF) and CD59 (membrane 
inhibitor of reactive lysis, MIRL) are widely expressed on 
all hemopoietic cells and are both involved in the regulation 
of complement activation. CD55 increases the removal of 
C3 convertase, thereby reducing the amount of C3 that is 
cleaved.14 CD59 inhibits C9 binding to C5b, C6, C7 and C8 
which together make up the MAC. The MAC is then inserted 
into the cell membrane causing cell lysis.
The absence or reduced expression of CD55 and CD59 
on PNH red blood cells leads to their increased sensitivity to 
complement mediated attack. This in turn causes the major-
ity of symptoms of the disease. Based on their sensitivity to 
complement attack, erythrocytes in PNH have been classi-
fied into 3 groups.14 Type I cells are normal red blood cells, 
type III cells have a complete deficiency of GPI anchored 
proteins and type II cells have a partial deficiency (Figure 3). 
The degree of hemolysis suffered by individuals is relative to 
the proportions of the type II and III cells present. In general, 
the larger the proportion of type III cells, the more severe the 
hemolysis suffered by the affected individual.
PNH diagnosis
As PNH is a rare disease, its precise incidence and prevalence 
has not been well documented. It is not unusual for patients to 
be misdiagnosed or remain undiagnosed for long periods. The 
most reliable data on the incidence and prevalence of the dis-
ease is from work undertaken in Yorkshire, England.15 In this 
study, the prevalence of patients with PNH clones of any size 
is 15.9 per million and the incidence is 1.3 per million of the 
total population. Eighty-two percent of these patients had a 
granulocyte clone size greater than 1%, with 43% of these 
greater than 10% and a quarter greater than 50%. Clone sizes 
down to 0.05% were detected in this study while evaluating 
a minimum of 1 × 106 flow cytometry events.
Initially, PNH diagnosis relied on a biochemical assay, 
the Ham test, in which red blood cells are exposed to acidified 
serum. Under these conditions, complement is activated 
via the alternative pathway and causes lysis of PNH cells 
as they are sensitive to complement attack.16 This test 
was time consuming, non-specific, insensitive and lacked 
standardization. It was succeeded by flow cytometry in 
the 1990s.
Flow cytometry is routinely performed to evaluate the 
size of erythrocyte and granulocyte clones and is considered 
the “gold standard” for diagnosing PNH. Peripheral blood 
granulocyte clone size is believed to be the best marker for 
evaluating the extent of affected HSCs in the bone marrow 
as the erythrocyte clone size can vary depending both on 
the degree of intravascular hemolysis present and whether 
an individual has had a recent red cell transfusion of normal 
erythrocytes. The granulocyte clone size also correlates well 
with the platelet clone size.
Initially, flow cytometry was used to look for the absence 
of specific GPI-linked proteins such as CD55 and CD5917 
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Figure 1 Glycophosphatidylinositol biosynthesis: an illustration showing the stepwise 
addition of sugar residues and the sites at which PIG-A and PIG-M are required.
Abbreviations: M, mannose; NA, N-acetylglucosamine; Pi, phosphatidylinositol.Therapeutics and Clinical Risk Management 2009:5 913
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and determination of the presence of these antigens is still 
routinely used in evaluating the proportion of PNH red blood 
cells present. The use of both of these targets in conjunction 
excludes rare single antigen deficiencies and allows a red 
cell clone as small as 0.01% to be detected.18 Evaluation of 
CD59 expression usually provides the clearest separation of 
type I, II and III red blood cells (Figure 3).
A wide variety of different GPI-linked proteins have 
been used to assess the PNH granulocyte clone size. The 
most recent development in this diagnostic field is the devel-
opment of the FLAER reagent.18 FLAER is a fluorochrome-
labeled inactive variant of the protein aerolysin which 
selectively binds directly to the GPI anchor. It cannot be 
used to ascertain the extent of the PNH red cell clone size 
as the presence of glycophorin, a non-GPI-linked protein on 
erythrocytes, binds to the FLAER non-specifically. FLAER 
can be used alone or in combination with other monoclonal 
antibodies to GPI-linked antigens to evaluate the granulo-
cyte clone size. At the moment there is no standardization 
for the diagnosis of PNH with a marked diversity seen in 
the antibodies used between different centers. FLAER is 
becoming increasingly used for granulocyte clone evaluation 
and provides a more accurate assessment, especially of small 
PNH clones.19 In our center, one of the 2 National Centers for 
treating PNH patients in England, we routinely use 6 color 
flow cytometry with a combination of FLAER, CD16, CD24, 
CD33, CD15 and CD14 for granulocyte analysis and CD59, 
CD55 and CD235a for evaluating erythrocyte clone sizes.
A standardized approach to PNH
A proposed classification to allow a standard approach to 
PNH patients for clinicians is to divide them into three 
distinct groupings.20
1. Classical PNH – these patients have the characteristic 
symptoms of PNH with intravascular hemolysis and a 
cellular bone marrow. They have no evidence of any 
other bone marrow pathology.
2. PNH in the setting of another specified bone marrow 
disorder – these patients have symptoms of intravascu-
lar hemolysis but also have, or have previously had, an 
underlying bone marrow abnormality such as aplastic 
anemia (AA) or myelodysplasia (MDS).
3. Subclinical PNH – these patients have no evidence of 
ongoing hemolysis. They have small PNH clones present 
and are often seen in patients with bone marrow failure 
especially in AA and MDS. These patients have been 
identified due to the development of improved diag-
nostic flow cytometry as prior to this these small clones 
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Figure 2 The complement cascade showing the proximal and the terminal complement components which lead to the formation of the membrane attack complex which in 
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would have remained undetected.19 The significance 
and relevance of subclinical PNH is unclear and will 
be evaluated in ongoing studies on otherwise healthy 
individuals.
The concern with this approach relates to the overlap 
between those with classical PNH that may have a small 
degree of aplasia and those with PNH in the setting of another 
specified bone marrow disorder that may have significant 
intravascular hemolysis.
The pathogenesis of PNH
There is good evidence to suggest that all patients who 
develop PNH have bone marrow failure (usually AA and 
occasionally MDS) either before or at the time their PNH 
is diagnosed.21,22 Since there is no definitive evidence that 
GPI deficient cells have an intrinsic survival advantage 
over normal cells, a cell extrinsic effect is likely to explain 
the preferential development of PNH clones concurrent 
with bone marrow failure.22 Bone marrow failure, AA in 
particular, appears to provide the environment needed for 
the expansion of PNH clones and small PNH clones can be 
found in up to two thirds of patients with AA.23
While the etiology of AA is often poorly defined, a pri-
mary role for immune mediated destruction of hemopoietic 
marrow elements is generally accepted. Consequently one 
of the main therapies used in AA is immunosuppression, 
via antithymocyte globulin and ciclosporin. The success 
of these therapies supports the proposed immune etiology. 
Furthermore, in vitro experiments demonstrate that removal 
of T-cells from aplastic bone marrow improves the number 
of colonies formed in tissue culture and analysis of these 
T-lymphocytes has identified them as activated cytotoxic 
T-cells (CTL).24 The cause of T-cell activation in AA is 
unknown but drug exposure and viral infection are potential 
candidates. The role of immune activation in AA leads to 
the hypothesis that immune evasion is a mechanism for the 
emergence of the PNH clone.
Some patients with PNH have multiple PNH clones 
detectable.25–27 Multiple clones are also found in those with 
PNH who have co-existing AA.28 Endo et al reported other 
features in relation to the presence of multiple clones.26 Their 
study identified four PIG-A mutations in one PNH patient 
and they proposed that the phenotypic mosaicism was due to 
genotypic mosaicism. They hypothesized that this genotypic 
mosaicism was due to hypermutability of the PIG-A gene.
In cases where multiple clones are present in a patient, one 
of these often makes up the majority of mature PNH cells. 
This domination of a single clone may be due to only one of 
the clones developing in the HSC pool,29 whereas the others 
are generated later during hemopoiesis in progenitor cells. 
Alternatively, accumulation of a dominant clone may reflect 
that an additional factor, not related to the PIG-A mutation, 
is responsible for clonal expansion.
Despite dramatic improvements in treating PNH, the 
underlying process that determines the expansion of PNH 
clones remains unclear. Occurrence of a PIG-A mutant clone 
is not sufficient for development of PNH, since these occur 
frequently in the normal population at very low levels.30 
In view of the association with bone marrow failure, and 
especially AA, it is likely that expansion of the clone is 
immune mediated. The simplest theory is that the immune 
attack in AA requires a GPI-linked protein and that absence 
of one of these proteins protects PNH cells from attack. 
Consequently, in the absence of a PIG-A mutant clone, an 
affected individual would present with AA, but in the pres-
ence of a PIG-A mutant clone, hemopoiesis is rescued and 
the individual presents with PNH, the clinical manifestations 
of PIG-A deficient hemopoietic cells.25 An alternative theory 
to this, involving the absence of specific GPI-linked proteins 
which provide a clonal advantage to PNH cells, has also 
been proposed.31 Hanaoka et al proposed that the absence 
of stress inducible proteins on PNH blood cells provide the 
basis for clonal expansion. Such a model however does not 
readily explain the link with AA, the failure of PNH clones 
to become dominant in normal individuals, and the lack of 
intrinsic proliferative advantage in vitro.
Inoue et al proposed a two stage model for the disease 
whereby clonal selection and clonal expansion occur by two 
separate events.32 In this model, clonal selection relates to 
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the PIG-A mutation, occurring in the setting of bone marrow 
failure with clonal expansion being due to a separate mutation 
within the PIG-A mutated HSC which confers a proliferative 
advantage.
Another potential mechanism that has been proposed is 
that lack of GPI molecules on PNH cells can render them 
resistant to apoptosis.33,34 However, other investigators have 
failed to observe this difference in apoptosis rates between 
GPI deficient and normal granulocytes.35
Furthermore, mouse models of PIG-A deficiencies do not 
develop clonal expansion of PNH-like cells.36,37 These results 
argue against a cell intrinsic role for PIG-A deficiency in the 
development of PNH. One clear explanation for the failure to 
develop a PNH-like syndrome is that these mouse models do 
not have underlying bone marrow failure or immune insult. 
Hence, the conditions for clonal expansion of PNH-like cells 
are not met.
Clinical symptoms and the role 
of nitric oxide
In general, the size of the PNH clone correlates with the 
degree of symptoms observed. Therefore, patients who 
have symptomatic PNH tend to have larger clones of 
PNH cells present. Affected individuals have chronic low 
grade hemolysis with episodes, or “paroxysms”, of severe 
intravascular hemolysis. During periods of intravascular 
hemolysis, free hemoglobin is released into the circulation. 
Haptoglobin, a protein produced mainly by hepatocytes in 
the liver, rapidly binds free hemoglobin and this haptoglobin–
hemoglobin complex is then degraded in the liver. This 
process is overwhelmed in PNH and leads to excess free 
hemoglobin avidly and irreversibly binding to nitric oxide 
(NO).38,39 NO plays an important role in the maintenance of 
vascular tone by relaxation of smooth muscle which conse-
quently causes blood vessel vasodilation. Depletion of NO 
in individuals with PNH leads to smooth muscle dystonia 
and this may be responsible for many of the symptoms of 
the disease. These include esophageal spasm and dysphagia, 
abdominal pain, severe lethargy and erectile dysfunction in 
men. NO depletion is associated with the development of a 
number of cardiovascular morbidities including pulmonary 
hypertension. Recently it has been shown that PNH patients 
have a high prevalence of pulmonary hypertension which 
is likely secondary to NO depletion.39
The clinical outcome of patients with PNH is highly vari-
able from one individual to the next. Thrombosis remains the 
commonest cause of death in the disease, occurring in 40% of 
patients, with a third of these being fatal.6,7 These thromboses 
predominantly occur in the venous system with an increase 
in thromboses in typical sites such as deep vein thromboses 
and pulmonary emboli as well as at unusual sites, such as 
the hepatic, mesenteric and cerebral veins.6 The arterial 
thrombosis risk is also elevated with increased occurrences 
of myocardial infarctions and strokes. Hall et al reported the 
risk of thrombosis in patients with a 50% or greater PNH 
clone to be 44%, and those with a less than 50% PNH clone 
to be 5.8%.40 Although the risk is far greater in those with 
larger PNH clones, even those with small clones (as low as 
10%) have a much higher thrombotic risk when compared 
with the general population.41,42
The underlying mechanisms causing thromboembolism 
in individuals with PNH has not been clearly defined and 
may be multifactorial in nature. NO depletion due to bind-
ing of NO to free hemoglobin causes both increased platelet 
aggregation and adhesion.38 Additionally, platelets lacking 
GPI-linked proteins are susceptible to complement mediated 
attack which leads to platelet activation and the formation 
and exocytosis of prothrombotic microvesicles containing 
the MAC.43 These microvesicles have been shown to be 
present at high levels in the blood of patients with PNH.44 
Another potential cause for the increased thrombotic risk is 
due to GPI deficient neutrophils lacking urokinase type plas-
minogen activator thereby reducing plasminogen activation 
and causing a reduction in fibrinolysis.45 It is likely that the 
increased thrombotic risk in PNH is due to a combination of 
these factors rather than a single underlying mechanism.
PNH treatment
Allogeneic bone marrow transplantation is the only cura-
tive therapy for PNH.46–48 However it carries a high rate of 
mortality and morbidity due to infection, graft versus host 
disease and graft failure. It is only an option for a minority 
of patients either because they are not suitable candidates 
for the procedure, a donor is unavailable or treatment with 
eculizumab may be deemed more appropriate. The introduc-
tion of eculizumab treatment plus the fact that around 15% 
of patients with PNH undergo a spontaneous remission of 
the disease, result in transplantation only being undertaken 
in specific circumstances.6 Transplantation should be consid-
ered when there is an associated severe bone marrow failure, 
life-threatening hemolysis with no access to eculizumab, 
recurrent thromboses despite eculizumab treatment and in 
cases of syngeneic twins.
Prior to eculizumab, the mainstay of treatment for patients 
with PNH has been supportive in nature. Folic acid is rou-
tinely taken, as in other hemolytic anemias, in view of the Therapeutics and Clinical Risk Management 2009:5 916
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increased red cell production. Many patients have become 
transfusion dependent in an effort to alleviate symptoms 
related to their anemia. Some of these patients have devel-
oped iron overload due to the number of transfusions and 
require treatment with iron chelation. The majority, however, 
remain in an iron deficient state due to their persistent hemo-
globinuria and therefore need to take oral iron supplements. 
In those patients with a large PNH clone, warfarin therapy 
has been employed, which can reduce the risk of developing 
thrombosis.40
Eculizumab
Eculizumab is a humanized monoclonal antibody that binds 
to the complement protein C5 and prevents its cleavage into 
C5a and C5b. It is comprised of murine complementarity-
determining regions within a human antibody framework that 
includes IgG2 and IgG4 regions. Treatment with eculizumab 
therefore prevents C5b formation which is necessary to form 
MAC through binding to the complement proteins C6, C7, 
C8 and C9. As the clinical features in PNH are caused by 
the MAC attack on erythrocytes, preventing its formation 
was likely to protect PNH red blood cells in the circulation 
(Figure 4). Information on the possible effects eculizumab 
might have in treating PNH was first seen in a case reported 
by Yonemura et al of a patient with co-existing PNH and 
a deficiency of C9.49 This patient was well with only mild 
hemolysis and only became unwell after receiving a whole 
blood transfusion after an operation. Transfusion of whole 
blood includes exogenous C9 allowing the symptoms of 
PNH to manifest.
The importance of both the proximal and the terminal 
complement proteins can be shown by examining people with 
rare inherited complement protein deficiencies. Congenital 
deficiencies of proximal complement proteins result in recur-
rent severe infections and death early in life.50 Deficiencies 
of the terminal complement proteins, C5, C6, C7, C8 or 
C9 increase the susceptibility to infection with the bacteria 
Neisseria meningitidis.50 In these individuals however, the 
proximal complement cascade remains intact allowing the 
formation of C3b and its subsequent opsonization and clear-
ance of most other bacteria.
C5 is a good therapeutic target as all the proximal comple-
ment pathways converge at C5 (Figure 2). Complement 
blockade at C5 will therefore halt the complement cascade 
preventing activation of the terminal complement compo-
nents no matter which initial pathway has been activated.
Eculizumab was initially evaluated in the treatment 
of patients with rheumatoid arthritis and systemic lupus 
erythematosis.51,52 These early clinical studies provided 
information on the frequency of dosing as well as the doses 
required to provide complement blockade.
Clinical trials of eculizumab
The pilot study
Eleven patients were entered into this initial study in 2002 
to assess the effect of eculizumab in PNH patients.2 Indi-
viduals needed to have received 4 or greater red blood 
cell transfusions in the preceding 12 months to enter the 
study. Patients were also vaccinated against N. meningitidis 
(serotypes A + C).
Eculizumab was administered at a dose of 600 mg 
weekly for the first 4 weeks followed by a dose of 900 mg 
every fortnight from the 5th week onwards. Data were col-
lected on the drug pharmacokinetics and pharmacodynamics, 
markers of hemolysis (lactate dehydrogenase (LDH), 
haptoglobin and bilirubin), hemoglobin and reticulocyte 
levels, PNH clone size proportions as well as the degree 
of hemoglobinuria and the individual transfusion require-
ments. European Organization for Research and Treatment 
of Cancer (EORTC) questionnaires were employed to assess 
potential changes in quality of life. Concomitant medication 
such as immunosuppressive and anticoagulant medication 
was continued.
There was a dramatic reduction in LDH levels in these 
patients from a mean level of 3111 IU/L prior to treatment 
down to 594 IU/L in the study. The proportion of type III 
erythrocytes during the 12 weeks increased significantly 
from a mean of 36.7% to 59.2% which supports an increased 
survival of these cells due to the prevention of intravas-
cular hemolysis. Transfusion requirements reduced in all 
11 patients with 5 becoming transfusion independent for the 
entire trial period. Hemoglobinuria resolved in most and there 
was a rapid and sustained improvement in quality of life.
On completion of the pilot study these 11 patients all 
enrolled into a 12 month extension trial to evaluate the 
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long-term safety and efficacy of eculizumab.53 Complement 
blockade with a consequent sustained reduction in both 
intravascular hemolysis and transfusion requirement was 
observed during the extension period. The initial dramatic 
improvement in quality of life was also maintained. The 
use of eculizumab appeared to be safe and well tolerated in 
these patients.
The pilot study supported the importance of terminal 
complement activation in PNH and suggested that eculi-
zumab could be used to reduce hemolysis and transfusion 
requirements whilst increasing the proportion of type III 
erythrocytes and improving quality of life in this debilitat-
ing disease.
The TRiUMPH study
Following the success of the pilot study, a double-blind, 
randomized, placebo-controlled multicenter phase 3 trial 
(TRIUMPH) was undertaken.3 Patients could enter into a 
3 month observation period if they were more than 18 years 
old, had received four or more red cell transfusions in the 
preceding twelve months, had 10% PNH type III eryth-
rocytes present, a platelet count 100 × 109/L and an LDH 
level 1.5 times the upper limit of normal. Patients that were 
transfused during the observation period were then eligible 
to enter the study. Eighty-seven patients were randomized to 
receive either eculizumab or placebo for 6 months with 44 of 
these receiving eculizumab and the rest being given placebo 
infusions. At the end of the 26 week period patients who had 
been given placebo were allowed to cross-over and receive 
eculizumab. The protocol for administration of eculizumab 
was the same as in the pilot trial.
The TRIUMPH study was designed to see if eculizumab 
stabilized hemoglobin levels and reduced transfusion 
requirements. Secondary trial endpoints included assessment 
of intravascular hemolysis, fatigue and quality of life.
Stabilization of hemoglobin levels was achieved in 49% 
of the patients treated with eculizumab and this did not occur 
in any patient in the placebo group. Fifty-one percent of the 
study group remained transfusion independent throughout 
the 26-week study whereas all the placebo group patients 
had been transfused by the 14th week of the study. There 
was a 44% reduction in the number of transfusions needed 
by the patients who did not become transfusion independent 
on eculizumab. As in the pilot study, there was a marked 
reduction in intravascular hemolysis in the eculizumab 
group with LDH levels falling from a mean of 2199.7 IU/L 
to 327 IU/L. Levels in the placebo group remained high with 
a mean of 2418.9 IU/L during the 26 weeks. Fatigue was 
assessed using the Functional Assessment of Chronic Illness 
Therapy (FACIT) instrument and quality of life by EORTC 
questionnaires. Both showed huge improvements in those 
treated with eculizumab. Although the TRIUMPH study was 
not designed to look at thrombotic events, no thromboses 
occurred in the patients receiving eculizumab.
This study confirmed the importance of eculizumab in 
stabilizing hemoglobin levels, reducing or stopping the need 
for transfusions as well as improving anemia, fatigue and 
quality of life for PNH patients.
The SHePHeRD study
The SHEPHERD study was a phase 3 trial designed to 
evaluate the safety and efficacy of eculizumab in treat-
ing a more diverse population of patients with PNH 
including those with fewer transfusion requirements and 
thrombocytopenia.4 The trial entry criteria included patients 
transfused at least once in the preceding 2 years, a platelet 
count of 30 × 109/L, 10% PNH type III erythrocytes 
present and an LDH level 1.5 times the upper limit of 
normal. Ninety-seven patients were enrolled and 96 of 
these completed the 52 week study period. The protocol for 
administration of eculizumab was the same as in the pilot 
and the TRIUMPH trials.
Eculizumab was well tolerated with a similar rate of 
adverse events (AE) reported to the TRIUMPH study. 
The commonest AEs reported were headaches (53%), 
nasopharyngitis (32%) and upper respiratory tract infec-
tions (30%). The incidence of headaches was greater in 
the first 26 weeks (49%) of the study compared to the last 
26 weeks (15%). The majority of these headaches were 
mild to moderate in severity and most occurred only within 
the first 2 weeks of their eculizumab infusions. Forty-four 
serious AEs were reported but none were thought to be 
probably or definitely due to eculizumab though 7 of them 
were possibly related to the drug. These 7 events included 
2 of pyrexia, 1 of headache, 1 of abdominal distension, 1 of 
a viral infection, 1 of anxiety and 1 of renal impairment. Two 
patients, both with a prior history of thromboembolism, had 
a further thrombosis during the study. Eighty-nine patients 
(91%) had mild or moderate infections during the study with 
the majority of these thought to be unrelated to eculizumab. 
Low titer anti-eculizumab antibodies occurred in 2 patients 
(2%) but with no loss of drug efficacy.
Eighty-nine patients (91%) had serum eculizumab 
levels 35 µg/mL, throughout the trial period. This level 
has been shown to completely block terminal complement 
activation and prevent intravascular hemolysis.2 The other Therapeutics and Clinical Risk Management 2009:5 918
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8 patients experienced breakthrough hemolysis 1 to 2 days 
prior to their next eculizumab infusions, but after reducing 
the dosing interval from 14 to 12 days, consistent comple-
ment blockade was resumed. There was a marked reduction 
in intravascular hemolysis in the eculizumab group with LDH 
levels falling from a mean of 2201 IU/L to 297 IU/L and the 
proportion of type III erythrocytes present increased from a 
mean of 33.5% to 55.7%. Transfusion requirements reduced 
from a mean of 12.3 units per patient in the 12 months prior 
to the study to 5.9 units per patient, with 51% of patients 
remaining transfusion independent for the entire 52 weeks.
This trial shows that eculizumab appears to be safe and 
well tolerated and provides marked benefits to a broader group 
of PNH patients by reducing intravascular hemolysis.
Eculizumab: its effect 
on thromboembolism 
and renal function
Clinical trial patients from all three of these trials were 
entered into an extension study and the rate of thromboem-
bolism assessed.54 Thrombosis rates in these 195 trial patients 
were compared before and after treatment with eculizumab. 
Prior to eculizumab treatment this group had a thromboem-
bolic rate of 7.37 thromboses per 100 patient years. This 
decreased dramatically to 1.07 thromboses per 100 patient 
years with complement blockade. The question arises as to 
whether patients that are treated with eculizumab should also 
receive warfarin. Warfarin has been shown to reduce the risk 
of thrombosis in PNH but it also carries a significant risk 
(2% to 13%) of severe bleeding.55 Patients who have had a 
prior thrombosis have a high risk of subsequent thrombosis7,56 
and in view of this, these patients are often treated with both 
eculizumab and anticoagulation. However it remains unclear 
whether it is better to use eculizumab alone or in conjunction 
with anticoagulation in patients with PNH who have not suf-
fered a thrombosis and are deemed to be high-risk.
Renal damage is a common finding in patients with 
PNH and this damage may be due to repeated microvascular 
thrombosis, renal cortical hemosiderosis, repeated exposure 
of the kidney to heme proteins or reduced kidney perfusion 
due to the reduced availability of NO.57–60 The 195 patients 
from the PNH clinical trials were screened for evidence of 
chronic kidney disease (CKD) before and after 18 months 
of treatment with eculizumab.61 Sixty five percent (126/195) 
of patients had evidence of CKD and administration of 
eculizumab was generally associated with an improvement 
in renal function with 21% of patients with prior CKD no 
longer classified with CKD during eculizumab treatment. 
The patients with more mild baseline kidney disease were the 
most likely to have an improvement in their renal function.
Specific issues on eculizumab 
treatment
Neisseria meningitidis infection
One of the main concerns for physicians treating patients 
with eculizumab is that of infection with N. meningitidis. 
In the PNH clinical studies, 2 out of 195 patients experienced 
meningococcal sepsis. Both patients were treated promptly 
and remain well. Since the completion of these clinical trials 
there has been 1 fatality due to meningococcal sepsis. The 
risk of this infection is low and has been further reduced by 
vaccinating patients with the quadravalent vaccine against 
serotypes A, C, W and Y, prior to starting eculizumab. Unfor-
tunately at present there is no vaccine against serotype B 
which is a common strain of the bacteria in Europe. As in 
the TRIUMPH and SHEPHERD studies in our center we 
routinely give the patients two 750-mg doses of ciprofloxacin 
to keep at home and take if unwell while also seeking medical 
attention. It is important that both patients and physicians are 
educated and remain vigilant about the signs of the disease 
so that they seek and receive prompt targeted medical treat-
ment when needed.
Breakthrough hemolysis
A significant minority of patients treated with eculizumab 
develop symptoms of intravascular hemolysis 1 to 2 days prior 
to their next eculizumab infusion (around 7%–9% – personal 
experience). In some patients this can be resolved by reducing 
the treatment from every 14 days to every 12 days.2,4 Treatment 
every 12 days can be inconvenient as the day of treatment 
varies and infusions are also required at weekends. A 1200-mg 
dosing schedule every 14 days has been used in our center 
and found to consistently block complement even in patients 
who still have breakthrough symptoms on 900mg eculizumab 
every 12 days.62 Patients treated with this 1200 mg dose were 
found to have a good correlation between eculizumab and 
LDH levels, suggesting that a breakthrough in complement 
activity due to insufficient drug levels can be monitored by 
measuring LDH near the end of the dosing interval.
extravascular hemolysis
Despite the enormous health improvements seen in most 
patients with PNH there are some patients that remain anemic 
and dependent on transfusions. This suboptimal response 
may be due to the complement protein C3 binding to PNH red Therapeutics and Clinical Risk Management 2009:5 919
eculizumab for treatment of PNH Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
blood cells causing an increase in extravascular hemolysis.63 
Co-existent bone marrow failure is also likely to be con-
tributory. Eculizumab blocks the formation of the terminal 
components of the complement cascade but has no effect on 
the proximal components. The absence of CD55 (DAF) on 
the surface of the PNH red cells means the usual regulation 
and accelerated decay of cleaved C3 products is disrupted 
and the red cells are bound with C3. This phenomenon has 
emerged with the use of eculizumab as prior to it these blood 
cells were likely to hemolyzed intravascularly.
Pregnancy
Pregnancy carries an increased risk of mortality and morbidity 
in PNH compared with the non-pregnant state.64–66 The main 
risks to the mother are in the form of thromboembolism and 
infection, whereas in the baby most complications relate to 
prematurity which occurs in around half of pregnancies to 
mothers with PNH. Eculizumab has been used in pregnancy 
in one patient during the third trimester.67 It has also been 
used for the first time from conception and through the entire 
pregnancy.68 In this case eculizumab was not detected in the 
cord blood or breast milk, suggesting it does not cross the 
placenta or into mother’s milk. The use of eculizumab in 
pregnancy will become an increasingly frequent conundrum 
as more young women treated with the drug feel well enough 
to consider starting a family.
Conclusion and summary
Eculizumab has dramatically changed the way clinicians 
approach treatment for patients with PNH. It took just 5 years 
from the pilot study in 2002 to the drug gaining its Food and 
Drugs Administration license and its European Medicines 
Agency license in March and June 2007 respectively. The 
eculizumab clinical trials have shown that it is safe and well 
tolerated and provides huge benefits for PNH patients who 
previously received supportive therapies. It has been shown 
to stop intravascular hemolysis and the subsequent symptoms 
patients develop, reduce or abolish the need for transfusions, 
stabilize hemoglobin levels, improve patient quality of 
life, reduce fatigue, reduce the risk of developing thromboses, 
protect against worsening renal function and decrease pulmo-
nary hypertension. It is likely that in the future eculizumab 
will improve patient mortality.
Although it has many positive points, there are some 
negatives to eculizumab treatment. It has to be given as 
an intravenous infusion every 2 weeks, there is a small 
but definite increase in susceptibility to N. meningitidis, it 
costs ∼ US$400,000 per year and it does not cure the disease. 
Eculizumab is of use in treating classical PNH, ie, where 
hemolysis is the predominant disease component. It does 
not have a role in the treatment of patients with subclinical 
PNH with no evidence of hemolysis.
Further research into PNH is needed to ascertain why and 
how it occurs and may allow future therapies to be developed 
to cure the disease. For the time being, eculizumab provides 
patients who have previously suffered with a chronic illness 
the ability to lead normal family and working lives within 
their communities.
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